MRNA

Company overview unavailable

$145.55

-$3.32 (-2.23%)

Last close · 2026-09-04

Free AI rating for MRNA

See QuantAdvisor's buy/sell/hold call and the reasoning — no account needed.

Price history

Daily closing prices for MRNA.

+$97.95 (+205.78%) over the last 3m

$200.00$200.00$150.00$150.00$100.00$100.00$50.00$50.00$0.00$0.002026-06-082026-06-082026-06-222026-06-222026-07-062026-07-062026-07-172026-07-172026-07-302026-07-302026-08-122026-08-122026-08-252026-08-25

Related news

Recent coverage of MRNA.

Summer Flings And Heartbreaks

Since the close on the Thursday before Memorial Day, the S&P 500 has rallied 3.7%. Read more here.

SeekingAlpha · 15h ago

What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?

Moderna (NasdaqGS:MRNA) has started a Phase 3 trial of its mRNA based bird flu vaccine, moving the program into late stage testing. The trial is supported by a major international partnership focused on pandemic preparedness. Moderna has tied the program to commitments for equitable global access, including reserved manufacturing capacity for low and middle income countries. This push into mRNA vaccines for emerging infectious diseases points to a wider theme in healthcare that is worth...

Yahoo · 1d ago

Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?

Moderna (MRNA) drew fresh attention after completing a US$2.6b zero coupon convertible notes offering due 2032 and separately announcing an additional US$2b 2032 convertible notes issue, both placed under Rule 144A. Moderna's recent completion of zero coupon notes and the additional 2032 convertible announcement come after a surge in momentum, with the share price delivering a 30 day return of 158.73% and a year to date share price return of 371.65%, while the 1 year total shareholder return...

Yahoo · 1d ago

Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?

The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.

Yahoo · 1d ago

Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run

Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current price already reflects much of the good news around the mRNA pipeline. The share price return over the past 12 months is above 500%, which sets a high bar for what future progress on products and earnings needs to justify. Recent approvals for updated COVID vaccines and the first mRNA flu shot,...

Yahoo · 1d ago

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo · 2d ago

Stay updated with the S&P500 stocks that are on the move in today's pre-market session.

Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.

ChartMill · 2d ago

GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says

GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...

Yahoo · 2d ago

Key statistics

Company fundamentals are temporarily unavailable.

StockTwits chatter

What traders are saying on StockTwits right now

No StockTwits chatter available right now.

Source: StockTwits

Community

Recent posts mentioning MRNA.

Sign in to join the QuantAdvisor conversation on MRNA — post your take, like and follow.

Data may be delayed. For research, not financial advice.

© 2026 QuantAdvisor. All rights reserved.